RPL22

Across TCGA pan-cancer cohorts, RPL22 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of RPL22’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where RPL22 RNA is repressed in tumor relative to normal tissue. In most cancer types RPL22 is over-expressed in tumor, although a few such as BRCA and UCEC show the opposite, repressed pattern.

BRCA, LIHC, and UCEC are the cancer types where RPL22 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL22 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	Female	II,III,IV	−0.484	<.001	8	view →
LIHC	All	II,III,IV	+0.505	<.001	7	view →
UCEC	All	All	−1.144	<.001	6	view →
KICH	Female	All	−1.592	<.001	5	view →
LUSC	Male	II,III,IV	+0.526	.008	5	view →
THCA	All	All	−0.232	<.001	4	view →
CHOL	Male	All	+1.438	<.001	3	view →
KIRC	All	All	+0.242	.002	3	view →
KIRP	Male	All	−0.439	.002	2	view →
BLCA	All	IV	−0.322	.017	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

RPL22–BRCA

Open the BRCA breakdown →